Literature DB >> 3569410

In vitro binding of the very potent and selective D-2 dopamine agonist, [3H]N-0437 to calf caudate membranes.

J Van der Weide, J B De Vries, P G Tepper, A S Horn.   

Abstract

N-0437, a non-catecholic aminotetralin has recently been described as a very potent and selective dopamine D-2 agonist. In this study the in vitro binding of [3H]N-0437 (specific activity 80.6 Ci/mmol) to calf caudate membranes is described. It was found that [3H]N-0437 binds with a high affinity (KD = 0.17 nM) and a low proportion of non-specific binding. Moreover the binding was saturable with a high number of binding sites (Bmax = 703 +/- 28 fmol/mg protein) and reversible (dissociation half-time = 68 min). Pharmacological analysis of [3H]N-0437 binding showed that it was selective for dopamine receptors and that it was also stereoselective for D-2 receptors. Non-dopaminergic drugs were without exception very poor displacers. Taken together the results suggest that [3H]N-0437 labels dopamine D-2 receptors with a high selectivity in the calf brain, and thus, that it should be a useful tool in studies of central dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569410     DOI: 10.1016/0014-2999(87)90167-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.

Authors:  Martyn Wood; Vanessa Dubois; Dieter Scheller; Michel Gillard
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

2.  Development of a radioreceptor assay for the D2-selective dopamine agonist N-0437.

Authors:  K Ensing; D A Bloemhof; W G in 't Hout; J van der Lende; R A de Zeeuw
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

3.  Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm Gen Sect       Date:  1990

4.  The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease.

Authors:  Dieter Scheller; Christoph Ullmer; Reinhard Berkels; Mirella Gwarek; Hermann Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-14       Impact factor: 3.000

5.  Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model.

Authors:  I den Daas; P G Tepper; H Rollema; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

6.  Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.

Authors:  T B Mulder; J B de Vries; D Dijkstra; J W Wiechers; C J Grol; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

7.  Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: the in vitro and in vivo activity of eight ester prodrugs.

Authors:  I den Daas; P G Tepper; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.